Last reviewed · How we verify
NCT06675422: JY231
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Phase 1, PHASE2 trial testing JY231 injection in Systemic Lupus Erythematosus (SLE) in 20 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 9 October 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- JY231 injection
Conditions studied
- Systemic Lupus Erythematosus (SLE) — all drugs for Systemic Lupus Erythematosus (SLE) →
Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Who can join
Adults 14 to 75, any sex, with Systemic Lupus Erythematosus (SLE). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.
Natoli V, Charras A, Smith EM, Hedrich CM. · · 2025 · cited 1× · PMID 41410901 · DOI 10.1007/s11926-025-01207-7 -
Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.
He L, Sun Y, Ma B, Lang G, et al · · 2026 · PMID 42093990 · DOI 10.3389/fimmu.2026.1772428
Verify or expand the search:
- PubMed search for NCT06675422
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Lupus Erythematosus (SLE)
Currently open trials in the same condition.
- NCT07447986 — To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus · Phase 2 · recruiting
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · Phase 3 · recruiting
- NCT06875960 — A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis · Phase 4 · recruiting
Other 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials
Trials by the same sponsor.
- NCT06514768 — JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) · EARLY_PHASE1 · recruiting
- NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
- NCT06210243 — C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma · Phase 1 · terminated
- NCT06110208 — Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML · EARLY_PHASE1 · terminated
- NCT05932173 — A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06675422 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Last refreshed: 5 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06675422.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing